Brands of Doripenem in Kenya

Dorinem, Kenpharma Healthcare Ltd

Teicondo, M.J. Biopharm Pvt. Limited

Doripenem in Kenya : Brands, Uses Price in Kenya, Generics
Doripenem Chemical Structure


Doripenem is a penem antibacterial indicated in the treatment of the following infections caused by designated susceptible bacteria:

    • Complicated intra-abdominal infections

Doripenem is indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros.

    • Complicated urinary tract infections, including pyelonephritis

Doripenem is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumann.


The recommended dosage of Doripenem is 500 mg administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age.

Complicated intra-abdominal infection 500 mg every 8 hours  (infussed for 1 hour ) 5–14 days

Complicated UTI, including pyelonephritis 500 mg every 8 hours (infussed for 1 hour ) 10 days


Patients with known serious hypersensitivity to doripenem or to other drugs in the same class or patients who have demonstrated anaphylactic reactions to beta-lactams


Valproic Acid

Co-administration of Doripenem with valproic acid causes the serum concentrations of valproic acid to fall below the therapeutic range, increasing the risk for breakthrough seizures. Although the mechanism of this interaction is not fully understood, data from in vitro and animal studies suggest that doripenem may inhibit the hydrolysis of valproic acid’s glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the plasma concentrations of valproic acid. This is consistent with case reports for other carbapenems, where serum concentrations of valproic acid were reduced upon co-administration with a carbapenem. If administration of Doripenem is necessary, supplemental anti-convulsant therapy should be considered. The pharmacokinetics of doripenem were unaffected by the co-administration of valproic acid.


Probenecid interferes with the active tubular secretion of doripenem, resulting in increased plasma concentrations of doripenem.
Coadministration of probenecid with Doripenem is not recommended.

Drugs metabolized by cytochrome P450 cytochrome P450 enzymes

Doripenem neither inhibits nor induces major cytochrome P450 cytochrome P450 enzymes


Hypersensitivity Reactions

Serious and occasionally fatal hypersensitivity (anaphylactic) and serious skin reactions have been reported in patients receiving beta-lactam antibiotics. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. Before therapy with Doripenem is instituted, careful inquiry should be made to determine whether the patient has had a previous hypersensitivity reaction to other carbapenems, cephalosporins, penicillins or other allergens. If this product is to be given to a penicillin-or other beta-lactam-allergic patient, caution should be exercised because cross-reactivity among beta-lactam antibiotics has been clearly documented. If an allergic reaction to Doripenem occurs, discontinue the drug.

Serious acute hypersensitivity (anaphylactic) reactions require emergency treatment, as clinically indicated


Seizures have been reported during treatment with doripenem . In clinical trials, doripenem-treated patients with pre-existing central nervous system (CNS) disorders (e.g. stroke or history of seizures), patients with compromised renal function and patients given doses greater than 500 mg every 8 hours appear to be at greater risk for developing seizures.


Most common adverse reactions (≥ 5%) are headache, nausea, diarrhea, rash and phlebitis.

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, or clicking below button:

Doripenem in Kenya
Doripenem in Kenya
Doripenem in Kenya
Doripenem in Kenya
Doripenem in Kenya
Doripenem in Kenya

Clinical | Pharmacokinetic data

Pregnancy Category: B (No risk in non-human studies)
Routes of Administration: IM, IV
Bioavailability: Not Available
Protein Binding: 8.1%
Metabolosim: Renal
Onset of Action: N/A
Elimination Half life: 1 hour
Excretion: Renal

Legal Status | Dosage forms & Strengths

Prescription Category:
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:

Drug Indentifiers:

CAS Number
PubChem CID
CompTox Dashboard (EPA)

Drug Images

References/ Citation:

What was the patient being treated for
%d bloggers like this: